Recent Updates
Recently added Catalysts

Icalcaprant

Phase 2

Major Depressive Disorder | Small molecule | Psychiatry |AbbVie Inc.|Last Updated: May 13, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment195
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07276997A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive DisorderPHASE2 RECRUITING 195Dec 18, 2025Sep 1, 2027May 13, 202633 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score.
Up to approximately 6 weeks

Montgomery-Åsberg Depression Rating Scale (MADRS) The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are to be rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item will be scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity.

Number of Participants with Adverse Events (AEs)
Up to approximately 10 weeks

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

Secondary Endpoints
Change from Baseline in Clinical Global Impression (CGIS)
Up to approximately 6 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Icalcaprant Dose AEXPERIMENTALParticipants will receive oral Icalcaprant dose A once daily for 6 weeks and attend a follow up visit 30 days following end of treatment.
Icalcaprant Dose BEXPERIMENTALParticipants will receive oral Icalcaprant dose B once daily for 6 weeks and attend a follow up visit 30 days following end of treatment.
Placebo for IcalcaprantPLACEBO_COMPARATORParticipants will receive oral placebo once daily for 6 weeks and attend a follow up visit 30 days following end of treatment.
Interventions
NameTypeDescription
IcalcaprantDRUGOral Capsules
Placebo for IcalcaprantDRUGOral Capsules
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites33

Inclusion Criteria: * Participants with a diagnosis of major depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, text revision (DSM-5-TR) without psychotic features, confirmed by the Mini International Neuropsychiatric Interview (MINI) 7....

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07276997primaryCompletionDate: changed
LOWMay 24, 2026NCT07276997studyFirstPostDate: changed